A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
New draft guidance could see the agency getting ever stricter.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Posters and mini-orals include another VEGF bispecific.
